Analyst Ratings January 30, 2026

Baird Lifts Regeneron Price Target to $742 After Q4 Beat, Keeps Neutral Rating

Analysts revise outlook as Eylea HD and Dupixent drive confidence; multiple 2026 catalysts noted

By Avery Klein REGN
Baird Lifts Regeneron Price Target to $742 After Q4 Beat, Keeps Neutral Rating
REGN

Baird increased its price target on Regeneron Pharmaceuticals to $742.00 from $630.00 following a fourth-quarter 2025 report that topped expectations for revenue and profit, while retaining a Neutral rating. The move comes amid stronger-than-expected performance from Eylea HD and continued momentum for Dupixent, and follows a wave of analyst updates that reflect divergent views on the company’s near-term franchise dynamics and longer-term catalysts.

Key Points

  • Baird raised its price target on Regeneron to $742.00 from $630.00 while maintaining a Neutral rating; the target is near the current share price of $743.02.
  • Regeneron’s fourth-quarter 2025 results exceeded expectations for revenue and profit, with seven analysts recently increasing earnings estimates for the upcoming period.
  • Analysts cited strong Eylea HD performance and continued Dupixent strength; multiple 2026 catalysts were identified, including melanoma combination therapy data and C5 franchise results.

Baird has raised its price objective on Regeneron Pharmaceuticals (REGN) to $742.00 from $630.00, but the research firm stopped short of upgrading its recommendation, keeping a Neutral rating on the shares. The new target sits in close proximity to the stock’s most recent quoted level of $743.02.

The price-target increase follows Regeneron’s fourth-quarter 2025 earnings release, which beat analyst projections on both the top and bottom lines. According to available data, seven sell-side analysts have recently lifted their earnings estimates for the upcoming reporting period, indicating growing confidence in the company’s near-term financial trajectory.

Baird’s note singled out Eylea HD as a standout performer in the quarter and emphasized that a prefilled syringe PDUFA related to the PFS formulation remains on schedule. The firm also pointed to ongoing strength from Dupixent as a contributor to the company’s results.

Looking further ahead, Baird identified several development and regulatory milestones that could serve as catalysts in 2026. These include clinical progress for a fianlimab and Libtayo combination therapy in melanoma and forthcoming data for Regeneron’s C5 franchise addressing geographic atrophy and paroxysmal nocturnal hemoglobinuria (PNH). The research note also states that Regeneron plans to initiate Phase 3 programs across multiple therapeutic areas, specifically metabolic, cardiovascular and bleeding disorders.

Other broker updates have tracked the mixed picture emerging from Regeneron’s quarterly preannouncement and subsequent disclosures. Management’s prerelease indicated a divergence within the Eylea family: Eylea 2mg revenue came in at $577 million versus $600 million that had been anticipated, while Eylea HD outperformed expectations with $506 million versus a $454 million consensus.

Those intra-franchise results have prompted a range of analyst reactions. Bernstein raised its price target to $916, citing a constructive view of Eylea HD despite a deceleration in its growth rate. Evercore ISI lifted its target to $875 and highlighted upside tied to Dupixent and an upcoming Eylea HD prefilled syringe launch. BofA Securities reiterated a Buy rating with an $860 target, referencing the recent financial disclosures and the company’s 2026 R&D guidance.

At the same time, some firms expressed caution. Raymond James adjusted its target to $820 while noting mixed outcomes across the Eylea franchise, and RBC Capital kept a $745 target, pointing to potential competitive dynamics in 2026. Collectively, these updates illustrate a balance of optimism about key growth drivers and concern about franchise-specific headwinds.


Sector and market context: The analyst activity and the company’s trial and regulatory pipeline are most relevant to the pharmaceutical and biotechnology sectors, as well as health-care equity investors tracking product-cycle and regulatory catalysts.

Risks

  • Eylea franchise variability - Eylea 2mg revenue missed expectations while Eylea HD outperformed, creating franchise-level uncertainty that affects ophthalmology revenues and related equities.
  • Competitive and execution risks in 2026 - Several firms flagged potential competition and mixed franchise performance that could pressure growth, particularly in ophthalmology and immunology markets.
  • Clinical and regulatory uncertainty - Planned Phase 3 starts across metabolic, cardiovascular and bleeding indications and upcoming data for pipeline programs represent milestones that carry binary outcomes and potential market impact.

More from Analyst Ratings

Bernstein Boosts SanDisk Price Target to $1,000 After Robust Q2; Peers Follow Suit Feb 2, 2026 Piper Sandler Sticks With Overweight on Robinhood as Shares Pull Back Feb 2, 2026 Bernstein Raises Verizon Target to $48, Cites Strong Subscriber and FWA Gains Feb 2, 2026 Cantor Fitzgerald Keeps $350 Target on AMD, Cites Data Center Momentum and Capacity Dynamics Feb 2, 2026 Jefferies Trims Apogee Therapeutics Price Target After OX40 Program Concerns Feb 2, 2026